Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will demonstrate the efficacy of agomelatine (AGO178) 25 mg and 50 mg in the
prevention of relapse in patients with Major Depressive Disorder (MDD). Eligible patients
will undergo open-label treatment for 20 to 26 weeks, depending on response to treatment.
Patients demonstrating stable response at the end of the open-label treatment phase will be
assigned to receive agomelatine or placebo for 52 weeks.